HDAC inhibitors as a single agent or a part of combination regimes have been explored in other solid and hematological tumors, such as NSCLC, gastrointestinal carcinoma, malignant pleural mesothelioma, neuroblastoma, AML, MDS, and so on.514. The gene discussed is HDAC9; the disease is acute myeloid leukemia.